Objective: Dihydropyridine calcium antagonists have been shown to retard atherogenesis in animal models and to prevent the development of early angiographic lesions in human coronary arteries. Endothelial dysfunction is an early event in the pathogenesis of cardiovascular disease. We investigated whether nifedipine could improve endothelial function in hypercholesterolemia, independently of changes in blood pressure or plasma lipids. Methods: First, we compared in vivo forearm vascular responses to the endotheliumdependent and independent vasodilators serotonin (5-HT) and sodium nitroprusside (SNP) in 11 patients with familial hypercholesterolemia before and after 6-weeks treatment with nifedipine GITS (60 mg, OD) and in 12 matched controls. In a subgroup of six control subjects forearm vascular function was also assessed before and after 6-weeks nifedipine GITS treatment. In vitro, we subsequently explored possible mechanisms underlying the effect of nifedipine on endothelial function. We investigated the effects of nifedipine on 3 both NO production by recombinant endothelial NO synthase (eNOS) and endothelial cells, using H-arginine conversion, as well as on superoxide generation by endothelial cell lysates, using lucigenin enhanced chemiluminescence. Results: In hypercholesterolemia 5-HT-induced vasodilation was impaired (4769% increase in forearm bloodflow vs. 9968% in controls). Treatment with nifedipine completely restored 5-HT-induced vasodilation (113613%), whereas it did not influence basal forearm vasomotion or SNP-induced vasodilation. Nifedipine did not alter forearm vascular responses in control subjects and did not alter blood pressure or plasma lipids. In vitro, we found no direct effect of nifedipine on NO production by recombinant eNOS or endothelial cells. However, we did observe a reduction in endothelial superoxide generation. Conclusions: Our data show that nifedipine improves endothelial function in hypercholesterolemia. It is suggested from our in vitro experiments that this effect is due to reduced NO degradation.
Introduction
more, calcium antagonist drugs prevented the development of de novo angiographic lesions in human coronary arteries Dihydropyridine calcium antagonists are widely pre- [5, 6] . Both animal and human studies indicate that calcium scribed in the treatment of hypertension and angina antagonists may be effective in early atherogenesis. Inpectoris. Several studies have suggested an additional role deed, in vitro experiments demonstrated that calcium for these drugs as antiatherogenic agents. Calcium antagoantagonists interfere with early events in the development nists have been shown to retard atherogenesis in cholesof atherosclerosis, such as platelet aggregation [7] , terol-fed rabbits [1, 2] and monkeys [3] , independently of leucocyte-endothelial cell adhesion [8] , monocyte infiltrareduction of blood pressure or plasma lipids [4] . Furthertion of the subendothelium [9] , permeability of the endothelium [10] and / or media [11] and smooth muscle cell (SMC) migration [12, 13] and proliferation [14] [15] [16] . Inter-estingly, calcium antagonist drugs have been reported to again after 6 weeks treatment with nifedipine GITS, 60 mg reverse the impairment in endothelium-dependent, nitric once daily (Bayer, Germany). Nifedipine was not given on oxide (NO)-mediated vasorelaxation in hypercholesthe day of the study. During the study period (8 weeks) terolemic rabbits [4, 17] . Such an increase in NO availabilipatients received no lipid-lowering medication. In all ty may also attenuate the aforementioned early events in healthy controls forearm basal assessment of vascular atherogenesis [18] . function was performed (without treatment). In a subgroup Atherosclerotic vascular disease, but also major risk of six control subjects we also assessed the effects of 6 factors for atherosclerosis, including hypercholesterolemia, weeks nifedipine GITS (60 mg once daily) treatment on have been associated with endothelial dysfunction, charforearm vascular function. Experiments were performed in acterized by impaired endothelium-dependent, NO-media quiet, temperature controlled room (22-24.58C). All ated vasorelaxation [19, 20] . In hypercholesterolemia imexperiments were performed at the same time of the day. paired NO availability could be improved by lipid lowerAt least 12 h before each part of the study all subjects ing and / or antioxidant therapy [20] [21] [22] [23] . We hypothesized abstained from alcohol, tobacco and caffeine containing that treatment with the dihydropyridine calcium antagonist drinks. The study protocol was approved by the local nifedipine may improve NO availability in normotensive research committee of the University Hospital, Utrecht. All hypercholesterolemic patients with no overt macrovascular subjects gave written informed consent. The investigation disease, without affecting plasma lipid levels or blood conformed with the principles outlined in the Declaration pressure. To test our hypothesis we studied endotheliumof Helsinki. dependent and independent vasodilation in normotensive hypercholesterolemic patients and in healthy control subjects before and after 6 weeks treatment with nifedipine 2.1.3. Protocol GITS (slow release preparation). In addition, to explore Subjects were supine with both forearms resting slightly possible mechanisms underlying an effect on NO availabilabove heart level. After local anaesthesia a 22-g needle ity, we investigated the effect of nifedipine on NO was inserted into the brachial artery of the non-dominant production by endothelial nitric oxide synthase (eNOS) arm for blood pressure measurements and drug infusions. and endothelial cells and on NO degradation due to Drugs were dissolved in physiological saline (0.9%) and superoxide generation in endothelial cell lysates in vitro.
administered at a constant infusion rate of 1.3 ml / min. All solutions were prepared aseptically from sterile stock solutions or ampoules on the day of the study. Forearm 2. Methods blood flow (FBF) was measured in both arms at 15-s intervals by venous occlusion plethysmography using 2.1. Effects of nifedipine GITS on endothelial function in calibrated mercury in silastic strain-gauges, with a microvivo computer-based R-wave triggered system for on-line, semi-continuous monitoring [26] . Venous occlusion pres-2.1.1. Subjects sure averaged 40 mmHg. During each FBF determination Eleven patients with familial hypercholesterolemia the hands were excluded from the circulation by inflation (three females, one postmenopausal, two using oral anof wrist cuffs to suprasystolic pressure. FBF measurements ticonceptive medication), ranging in age from 19 to 49 were made at 5-or 6-min intervals. Measurements were (mean 37) years participated in our study. Familial hystarted at least 30 min after cannulation of the brachial percholesterolemia (FH) was defined as LDL-cholesterol artery, when FBF had stabilised. Between infusions, a of 4.5 mmol / l or more, VLDL-cholesterol of 2.0 mmol / l 15-20 min rest was applied to allow FBF to recover. or less and a family history of premature atherosclerosis or For assessment of endothelium-dependent vasodilation, tendon xanthomata [24] . In all our patients a molecular serotonin (5-HT, Sigma, St. Louis, MO, USA) was infused diagnosis of FH was established [25] . Twelve healthy into the brachial artery in increasing doses of 0-0.6-1.8-volunteers, matched for age and sex were included in our 6.0 ng / 100 ml forearm volume (FAV) / min. These dosages study as control group. Each participant in the study was have previously been shown to cause NO-mediated vasodiscreened by clinical history, physical examination and lation [20, 27] . For assessment of endothelium-independent routine chemical analyses; this revealed no evidence of vasodilation, sodium nitroprusside (SNP, Merck, Darmpast or present cardiovascular disease, hypertension or stadt, Germany) was administered intraarterially at indiabetes mellitus. Subjects had not used vasoactive medicremental doses of 0-6-60-180-600 ng / 100 ml FAV/ cation in the week before the study.
min. Serotonin-and sodium nitroprusside-induced vasodilation were assessed in randomized order to avoid any bias 2.1.2. Study design related to the order of drug infusion. Vascular function in the forearm of hypercholesPlasma total cholesterol, HDL-cholesterol, triglyceride terolemic patients was assessed after at least 2 weeks and apo-B were measured using standard laboratory methwithdrawal of maintenance lipid-lowering medication and ods.
Effect of local inhibition of the endogenous NO
was determined with BCA protein assay reagent (Pierce, system on serotonin induced vasodilation Rockford, Il, USA) using bovine serum albumin as a standard. Additional NOS activity experiments were perTo confirm that serotonin causes NO-mediated vasodiformed directly on the recombinant endothelial NOS lation, we performed an additional, separate series of enzyme, derived from a baculovirus / Sf9 expression sysexperiments in eight healthy volunteers. First, serotonin tem (Cayman, Ann Arbor, MI, USA), where the effects of was infused into the brachial artery in increasing doses of incubation with nifedipine (0, 10, 100 and 500 mmol / l) 0-0.6-1.8-6.0 ng / 100 ml FAV/ min. Subsequently, and BH (10 mmol / l) were studied. In these experiments 4 serotonin infusion was repeated during inhibition of the we used higher nifedipine concentrations because dihydroendogenous NO system in the forearm by use of a ''NO pyridines, due to their high lipid bilayer partitioning clamp'' [28, 29] . This ''NO clamp'' allowed us to simulate coefficients, may concentrate more than 1000-fold into normal basal NO activity during continuous inhibition of biological membranes [36] , the site of superoxide and NO endogenous NO synthesis. The ''NO clamp'' was obtained production. These experiments were performed in trip-G by continuous infusion of the NO synthase inhibitor L-Nlicate. monomethylarginine (L-NMMA; Institut fur Pharmazie, Universitat Leipzig, Germany), at a rate of 200 mg / 100 ml 2.4. Effects of nifedipine on superoxide generation by FAV/ min to achieve maximal inhibition of local NO endothelial cells synthase [20, 30, 31] , and subsequent coinfusion of incremental dosages of SNP, an exogenous NO donor until
The effects of nifedipine on superoxide generation by baseline forearm blood flow had been restored. L-NMMA human endothelial cells were investigated. HUVECs were and SNP were then coinfused at these rates for the isolated from umbilical cords as described previously [37] . remainder of the study. 
l). Cells endothelial cells and recombinant endothelial NOS
were then washed with Dulbecco's phosphate-buffered (eNOS) saline and suspended using a rubber policeman. To prepare total cell lysates, cells were homogenized in icecold The effect of nifedipine (Sigma) on endothelial NO Krebs-Ringer buffer with a 23-g needle. Superoxide production was studied in a human vascular endothelial generation was measured using lucigenin-enhanced chemicell line [32] that expresses eNOS. Cell monolayers were luminescence, as described previously [38] . In short, 2 grown to confluence in 175-cm culture flasks. The cells scintillation vials containing lucigenin (250 mmol / l) and were subsequently stimulated with the combination of cell lysates (10-30 mg protein) were placed into a Berthold TNFa (200 U / ml), Il-1b (5 U / ml) and IFNg (200 U / ml) luminometer (AutoLumat LB 953) at 378C, in the presence in the absence and presence of nifedipine [0.2 mmol / l, of 0.1 mmol / l NADH. Counts were recorded for 5 min dissolved in dimethylsulfoxide (DMSO)] for 24 h. This and the respective backgrounds were subtracted. Specifinifedipine concentration was similar to the estimated city of the chemiluminescence signal for superoxide was plasma concentrations obtained in vivo [33, 34] . Then cells controlled by incubation with superoxide dismutase (SOD, were suspended by brief treatment with trypsin-EDTA and 400 U / ml). All measurements were performed in dupliwashed with Dulbecco's phosphate buffered saline. To cate. prepare total cell lysates, cells were resuspended in cold lysis buffer (sucrose 0.3 mol / l, Hepes 10 mmol / l, 1% Triton, EDTA 0.1 mmol / l, dithiothreitol 1 mmol / l, 2.5. Analysis leupeptin 10 mg / ml, aprotinin 2 mg / ml, soybean trypsin inhibitor 10 mg / ml, and PMSF 50 mmol / l, pH 7.4), Average values of FBF (expressed as ml / 100 ml vortexed and kept at 48C [35] . NOS activity was deforearm volume / min) in the infused and non-infused arm
Serotonin-induced vasodilation after 6 weeks nifedipine ments. Results of in vitro experiments are presented as GITS in hypercholesterolemic patients was not signifimean6S.E.M. of two or three experiments. These data cantly different from controls (Fig. 1a) . In control subjects were examined by analysis of variance. If variance ratios 6 weeks nifedipine GITS treatment did not significantly reached statistical significance, differences between the alter serotonin-induced vasodilation (Fig. 2a) (Fig. 1b) . Nifedipine GITS treatment also cholesterol, triglycerides or basal FBF in hypercholesdid not significantly alter endothelium-independent vasterolemic patients (Table 1 ). There was also no significant orelaxation in control subjects (Fig. 2b ). effect of 6 weeks nifedipine GITS treatment on these parameters in the nifedipine-treated control subgroup (data not shown).
Effect of local inhibition of the endogenous NO system on serotonin induced vasodilation 3.1. Effects of nifedipine GITS on endotheliumdependent vasorelaxation in vivo
Infusion of serotonin during saline coinfusion caused significant vasodilation; the highest dose of serotonin Serotonin-induced vasodilation was significantly imincreased FBF (M / C ratio) by 77617% (FBFi: 2.660.5; paired in hypercholesterolemic patients compared to con- Data are expressed as mean6S.E.M. * P,0.05 vs. controls (t-test). There were no significant differences between hypercholesterolaemic patients before and after treatment (paired t-test). 
Discussion
The present study demonstrates that treatment with the dihydropyridine calcium antagonist nifedipine GITS restores endothelial function in hypercholesterolemic patients without overt vascular damage. The impaired serotonininduced, endothelium-dependent vasorelaxation in our group of hypercholesterolemic patients could be completely restored by nifedipine treatment, whereas nifedipine had no significant effect on the serotonin response in healthy control subjects. Nifedipine treatment also did not influence basal forearm vasomotion or nitroprusside-induced, endothelium-independent vasorelaxation. Importantly, the beneficial effect on endothelial function occurred without any changes in plasma lipid levels or blood pressure.
In the present study we used serotonin to assess endothelium-dependent vasodilation. Previous studies in hypercholesterolemia have shown impaired endothelium-dependent relaxation in response to acetylcholine, serotonin, substance P, but not to bradykinin [20, 40, 41] . The differ- . The present study confirms Incubation with 0.2 mmol / l nifedipine, which is similar previous observations [20, 27] that the vasodilator response to the concentrations obtained in vivo during nifedipine to serotonin is fully NO mediated. During ''NO clamp'' or GITS treatment, did not change NO production in endo-L-NMMA coinfusion serotonin-induced vasodilation is thelial cells (respectively from 0.8660.001 to 0.8460.04 completely abolished. In contrast, acetylcholine induced pmol / min / mg protein). Measurement of NO production vasodilation is only partially inhibited by L-NMMA codirectly on the recombinant eNOS enzyme yielded similar infusion, suggesting that this response is not only mediated results. NO production doubled from 64.662.1 to by NO, but is also due to release of other vascular factors, 139.860.5 pmol / min / mg protein after BH co-incubation such as prostaglandins and endothelium derived hyper-4 indicating that the sensitivity of the method is sufficient to polarizing factor. Therefore our data suggest a specific detect changes in NO-production. DMSO had no signifiimprovement of impaired NO bioavailability. cant effect on NO production (from 60.662.1 to 64.660. 6 Our observations are in agreement with other preliminpmol / min / mg protein). Co-incubation with nifedipine (10, ary reports. Kiowski et al. demonstrated that isradipine, 100, 500 mmol / l) also did not influence NO production by also a dihydropyridine calcium antagonist, could improve recombinant eNOS (from 64 an improvement of the impaired exercise-induced vasodichange from baseline. Nifedipine (0.2 mmol / l) reduced lation in hypertensive patients with coronary atherosclerosuperoxide generation by endothelial cell lysates by sis as well as in hypercholesterolemic patients after acute 2563%. Control experiments with SOD (400 U / ml) intracoronary calcium antagonist administration. However, reduced superoxide generation by 3961%, confirming that these results may have been due to an effect on vascular the observed lucigenin signal was indeed superoxide smooth muscle, resulting in facilitation of the vasodilator mediated.
response, rather than a beneficial effect on NO availability.
It is suggested that a beneficial effect on endothelial hypothesis we found that nifedipine reduced superoxide function or NO availability may be translated to a decrease generation in endothelial cells (lysates), a major deterin cardiovascular risk. NO has important antiatherogenic minant of impaired NO availability in hypercholesproperties and it has been shown that improvement of terolemia [23, 65, 66] . These observed antioxidant propendothelial function precedes structural regression of erties of dihydropyridine calcium antagonists are consistent atherosclerosis [47, 48] . Furthermore, similar functional with their chemical structure: they possess aromatic resoimprovement upon treatment with lipid lowering drugs was nance rings, a feature common to most classic chainparallelled by the outcome of clinical trials showing breaking antioxidants [67] and have high membrane reductions in acute cardiovascular events [20, 21, [49] [50] [51] [52] [53] [54] [55] .
partition coefficients, which may cause accumulation in Indeed, both the INTACT and Montreal Heart study membrane lipid bilayers, the main targets for oxidative demonstrated a reduction in the number of new coronary damage [68] . In agreement, calcium antagonists have lesions on angiography during calcium antagonist treatpreviously been shown to reduce lipid peroxidation, inment [5, 6] . In the REGRESS trial a synergistic effect of cluding formation of oxidised LDL, in vitro [67, [69] [70] [71] [72] ] calcium antagonists with lipid-lowering therapy in retardand to protect against free radical induced injury in ing the progression of coronary atherosclerosis has been cultured endothelial cells [70] and isolated rat hearts [73] . observed [56] . So far, several studies have shown a Mechanisms such as a modulatory role on endothelial beneficial effect of long-acting dihydropyridine calcium protein kinase C activity or improvement of the cellular antagonists on cardiovascular morbidity and mortality redox state by intracellular enzymatic induction may also [57, 58] , whereas others reported an increase in mortality in play a role in the antioxidant capacity of calcium antagopatients with coronary heart disease [59] . Currently ongonists. ing studies, like ALLHAT [60] and INSIGHT [61] will A limitation of the present study is that it was not a determine whether treatment with long-acting calcium randomized, placebo-controlled design. However, a nonantagonists has a beneficial effect on cardiovascular morspecific time effect is highly unlikely as endothelial bidity and mortality compared to other antihypertensive dysfunction assessed with our method has previously been agents.
shown to be a reproducible and consistent observation in Calcium antagonists inhibit voltage-gated L-type calcium time in FH patients [20] . Furthermore, while we observed channels in various cell types, thereby attenuating the a substantial improvement in endothelial function in our contractile effects of vasoconstrictors and facilitating the patient group, we did not find any alterations in the actions of endothelium-derived relaxant factors, like NO.
response in healthy controls. The inhibition of calcium influx in SMCs is the principal
In conclusion, our data demonstrate that nifedipine mechanism responsible for the therapeutic vasodilator improves endothelial function in hypercholesterolemia, effects of calcium antagonists in hypertension and angina independently of blood pressure or plasma lipid lowering pectoris [62] . However, such an effect on vascular smooth effects. It is suggested that this beneficial effect of muscle does not seem to be involved in our (normotensive) nifedipine is due to reduced NO catabolism. subjects as in our study no changes in blood pressure, heart rate or basal forearm bloodflow were induced by nifedipine GITS treatment, in agreement with previous observationsproduction, in canine coronary microvessels or large 
